Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 1, 2010, Pages

  Elez, Elena ^a   Alsina, Maria ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Diarrhoea; Late stage metastatic colorectal cancer; Metastatic colorectal cancer; Panitumumab; Response; Skin toxicity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; K RAS PROTEIN; PANITUMUMAB;

ACNE; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; INFUSION REACTION; LONG TERM CARE; MAINTENANCE THERAPY; PROGNOSIS; RASH; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77049122579     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70003-7     Document Type: Note

References (14)

1. Seront E., Marot L., Coche E., Gala J.-L., Sempoux C., and Humblet Y. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab. Cancer Treat Rev 36 Suppl 1 (2010) S11-S14
2. Merck Serono. Erbitux® (cetuximab) Summary of Product Characteristics. Available at http://emc.medicines.org.uk/medicine/19595/SPC/Erbitux+5mg+ml+solution+for+infusion/ Accessed 11 November 2009.
3. Tournigard C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24 (2006) 394-400
4. Chibaudel B., Maindrault-Goebel F., Lledo G., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27 (2009) 5727-5733
5. Labianca R., Floriani E., Cortesi L., et al. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial. J Clin Oncol ASCO Annual Meeting Proceedings 24 18S (2006) 3505
6. Bouché O., Beretta G.D., García Alfonso P., and Geissler M. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treat Rev 36 Suppl 1 (2010) S1-10
7. Segaert S., Chiritescu G., Lemmens L., Dumon K., Van Cutsem E., and Tejpar S. Skin toxicities of targeted therapies. Eur J Cancer 45 Suppl 1 (2009) 295-308
8. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
9. Amgen Ltd. Vectibix® (panitumumab) Summary of Product Characteristics. Available at http://www.emc.medicines.org.uk/medicine/20528/SPC/Vectibix/ Accessed 23 November 2009.
10. Mitchell E.P., Lacouture M., Shearer H., et al. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 27 18S (2009) CRA4027
11. Sartore-Bianchi A., Di Nicolantonio F., Nichelatti M., et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4 (2009) e7287
12. Laurent-Puig P., Cayre A., Manceau G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27 (2009) 5924-5930
13. Jacobs B., De Roock W., Piessevaux H., et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27 (2009) 5068-5074
14. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmaco-proteomic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010 Jan 25 [Epub ahead of print].